B. van Hille

发表

Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action

B. Hill, B. van Hille, C. Etiévant, 2000, Anti-cancer drugs.

Expression in Yeast and Purification of Functional Recombinant Human Poly(ADP-RIBOSE)Polymerase(PARP). Comparative Pharmacological Profile with that of the Rat Enzyme

B. Hill, B. van Hille, D. Perrin, 2000, Journal of enzyme inhibition.

Limitations to the expression of parvoviral nonstructural proteins may determine the extent of sensitization of EJ-ras-transformed rat cells to minute virus of mice.

B. van Hille, P. Tattersall, N. Salomé, 1989, Virology.

The ubiquitous VA68 isoform of subunit A of the vacuolar H(+)-ATPase is highly expressed in human osteoclasts.

B. van Hille, G. Bilbe, J. Green, 1995, Biochemical and biophysical research communications.

Partial reversion of conditional transformation correlates with a decrease in the sensitivity of rat cells to killing by the parvovirus minute virus of mice but not in their capacity for virus production: effect of a temperature-sensitive v-src oncogene

B. van Hille, N. Salomé, J. Rommelaere, 1989, Journal of virology.

Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK).

R. Herrmann, M. Fey, B. van Hille, 1997, European journal of haematology.

F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.

B. Hill, B. van Hille, C. Etiévant, 2000, Biochemical pharmacology.

Nonradioactive quantification of mdr1 mRNA by polymerase chain reaction amplification coupled with HPLC.

R. Herrmann, B. van Hille, R. Herrmann, 1995, Clinical chemistry.

Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database

J. Lortet-Tieulent, B. van Hille, M. Payet, 2021, Expert review of pharmacoeconomics & outcomes research.

Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France

B. van Hille, O. Heinzlef, P. Dourgnon, 2020, PharmacoEconomics - Open.

Heterogeneity of vacuolar H(+)-ATPase: differential expression of two human subunit B isoforms.

B. van Hille, G. Bilbe, J. Green, 1994, The Biochemical journal.

Decreased Nucleotide Excision Repair Activity and Alterations of Topoisomerase IIα Are Associated with the in Vivo Resistance of a P388 Leukemia Subline to F11782, a Novel Catalytic Inhibitor of Topoisomerases I and II

L. Créancier, B. Hill, B. van Hille, 2004, Clinical Cancer Research.

Assessment of drug-induced dysregulations among seven resistance-associated genes in human tumour cell lines.

R. Herrmann, B. van Hille, A. Lohri, 1996, Anticancer research.

Identification of two subunit A isoforms of the vacuolar H(+)-ATPase in human osteoclastoma.

D. B. Evans, B. van Hille, G. Bilbe, 1993, The Journal of biological chemistry.

Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents

B. Hill, B. van Hille, 1998, Cancer Chemotherapy and Pharmacology.

Initiation of transcription from the minute virus of mice P4 promoter is stimulated in rat cells expressing a c-Ha-ras oncogene

B. van Hille, J. Rommelaere, J. Cornelis, 1991, Journal of virology.

Cloning and tissue distribution of subunits C, D, and E of the human vacuolar H(+)-ATPase.

B. van Hille, G. Bilbe, J. Green, 1993, Biochemical and biophysical research communications.

Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes.

B. van Hille, N. Salomé, J. Rommelaere, 1990, Oncogene.

Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents.

B. Hill, B. van Hille, D. Perrin, 1998, Biochemical pharmacology.

mRNA expression, measured by quantitative reverse transcriptase polymerase chain reaction, of five putative drug resistance parameters, in normal and leukaemic peripheral blood and bone marrow.

R. Herrmann, B. van Hille, A. Tichelli, 1997, Acta haematologica.

The c-Ha-ras Oncogene Induces Increased Expression of β-Galactoside α-2,6-Sialyltransferase in Rat Fibroblast (FR3T3) Cells

V. Laudet, B. van Hille, E. Svensson, 1992 .

F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103

B. Hill, B. van Hille, C. Etiévant, 2000, Cancer Chemotherapy and Pharmacology.